Published in Oncogene on December 02, 2013
The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis. Nat Genet (2015) 1.04
NFI transcription factors interact with FOXA1 to regulate prostate-specific gene expression. Mol Endocrinol (2014) 0.96
Wnt signaling in castration-resistant prostate cancer: implications for therapy. Am J Clin Exp Urol (2014) 0.93
The lncRNA DRAIC/PCAT29 Locus Constitutes a Tumor-Suppressive Nexus. Mol Cancer Res (2015) 0.88
MicroRNA-99a and 100 mediated upregulation of FOXA1 in bladder cancer. Oncotarget (2014) 0.88
FOXA1 modulates EAF2 regulation of AR transcriptional activity, cell proliferation, and migration in prostate cancer cells. Prostate (2015) 0.86
Constitutive activity of the androgen receptor. Adv Pharmacol (2014) 0.84
Prostate Cancer Stem-like Cells Contribute to the Development of Castration-Resistant Prostate Cancer. Cancers (Basel) (2015) 0.79
FOXA1 regulates androgen receptor variant activity in models of castrate-resistant prostate cancer. Oncotarget (2015) 0.79
microRNA-625 inhibits tumorigenicity by suppressing proliferation, migration and invasion in malignant melanoma. Oncotarget (2017) 0.79
FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer. Proc Natl Acad Sci U S A (2016) 0.78
Drug discovery in advanced prostate cancer: translating biology into therapy. Nat Rev Drug Discov (2016) 0.78
Moving Beyond the Androgen Receptor (AR): Targeting AR-Interacting Proteins to Treat Prostate Cancer. Horm Cancer (2016) 0.77
Refinement of the androgen response element based on ChIP-Seq in androgen-insensitive and androgen-responsive prostate cancer cell lines. Sci Rep (2016) 0.76
Pyranocoumarin Tissue Distribution, Plasma Metabolome and Prostate Transcriptome Impacts of Sub-Chronic Exposure to Korean Angelica Supplement in Mice. Am J Chin Med (2016) 0.75
An Examination of the Association between FOXA1 Staining Level and Biochemical Recurrence following Salvage Radiation Therapy for Recurrent Prostate Cancer. PLoS One (2016) 0.75
Role of steroid receptor and coregulator mutations in hormone-dependent cancers. J Clin Invest (2017) 0.75
Identification of cis-regulatory mutations generating de novo edges in personalized cancer gene regulatory networks. Genome Med (2017) 0.75
Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A (2005) 167.46
Bioconductor: open software development for computational biology and bioinformatics. Genome Biol (2004) 143.19
Cancer statistics, 2012. CA Cancer J Clin (2012) 87.38
An integrated encyclopedia of DNA elements in the human genome. Nature (2012) 64.73
Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med (2011) 27.58
Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med (2012) 20.79
STRING 8--a global view on proteins and their functional interactions in 630 organisms. Nucleic Acids Res (2008) 20.62
Molecular determinants of resistance to antiandrogen therapy. Nat Med (2003) 18.90
Genome-wide analysis of estrogen receptor binding sites. Nat Genet (2006) 18.63
FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription. Cell (2008) 14.18
The mutational landscape of lethal castration-resistant prostate cancer. Nature (2012) 11.82
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet (2012) 9.93
Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell (2009) 7.09
MEME-ChIP: motif analysis of large DNA datasets. Bioinformatics (2011) 6.52
Reprogramming transcription by distinct classes of enhancers functionally defined by eRNA. Nature (2011) 6.10
beadarray: R classes and methods for Illumina bead-based data. Bioinformatics (2007) 6.08
Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell (2005) 6.04
A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. Mol Cell (2007) 5.99
Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. Nature (2012) 5.84
FOXA1 is a key determinant of estrogen receptor function and endocrine response. Nat Genet (2010) 5.22
ChIP-seq: using high-throughput sequencing to discover protein-DNA interactions. Methods (2009) 4.69
Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence. J Cell Biochem (2004) 3.51
Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer. Endocr Relat Cancer (2004) 3.03
The role of hepatocyte nuclear factor-3 alpha (Forkhead Box A1) and androgen receptor in transcriptional regulation of prostatic genes. Mol Endocrinol (2003) 3.01
The androgen receptor induces a distinct transcriptional program in castration-resistant prostate cancer in man. Cancer Cell (2012) 2.59
Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancer. EMBO J (2011) 2.55
Endogenous purification reveals GREB1 as a key estrogen receptor regulatory factor. Cell Rep (2013) 2.37
Forkhead box A1 regulates prostate ductal morphogenesis and promotes epithelial cell maturation. Development (2005) 2.31
Intragenic rearrangement and altered RNA splicing of the androgen receptor in a cell-based model of prostate cancer progression. Cancer Res (2011) 2.25
Genomic androgen receptor-occupied regions with different functions, defined by histone acetylation, coregulators and transcriptional capacity. PLoS One (2008) 2.18
The androgen receptor recruits nuclear receptor CoRepressor (N-CoR) in the presence of mifepristone via its N and C termini revealing a novel molecular mechanism for androgen receptor antagonists. J Biol Chem (2004) 2.15
Cooperative interaction between retinoic acid receptor-alpha and estrogen receptor in breast cancer. Genes Dev (2010) 2.06
Androgen receptor coregulators and their involvement in the development and progression of prostate cancer. Int J Cancer (2007) 1.94
BASH: a tool for managing BeadArray spatial artefacts. Bioinformatics (2008) 1.90
Definition of a FoxA1 Cistrome that is crucial for G1 to S-phase cell-cycle transit in castration-resistant prostate cancer. Cancer Res (2011) 1.89
HOXB13 induces growth suppression of prostate cancer cells as a repressor of hormone-activated androgen receptor signaling. Cancer Res (2004) 1.83
FoxA1 specifies unique androgen and glucocorticoid receptor binding events in prostate cancer cells. Cancer Res (2012) 1.72
Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1. EMBO J (2011) 1.72
The hepatocyte nuclear factor 3 alpha gene, HNF3alpha (FOXA1), on chromosome band 14q13 is amplified and overexpressed in esophageal and lung adenocarcinomas. Cancer Res (2002) 1.60
Regulation of androgen receptor activity by the nuclear receptor corepressor SMRT. J Biol Chem (2002) 1.56
Androgen receptor (AR) aberrations in castration-resistant prostate cancer. Mol Cell Endocrinol (2012) 1.53
Androgen receptor-independent function of FoxA1 in prostate cancer metastasis. Cancer Res (2013) 1.26
Persistent androgen receptor-mediated transcription in castration-resistant prostate cancer under androgen-deprived conditions. Nucleic Acids Res (2012) 1.24
FOXA1 promotes tumor progression in prostate cancer and represents a novel hallmark of castration-resistant prostate cancer. Am J Pathol (2011) 1.20
Heterogeneous nuclear ribonucleoprotein C1/C2, MeCP1, and SWI/SNF form a chromatin remodeling complex at the beta-globin locus control region. Proc Natl Acad Sci U S A (2005) 1.15
FOXA1 is a potential oncogene in anaplastic thyroid carcinoma. Clin Cancer Res (2009) 1.14
Non-overlapping progesterone receptor cistromes contribute to cell-specific transcriptional outcomes. PLoS One (2012) 1.09
High-level expression of forkhead-box protein A1 in metastatic prostate cancer. Histopathology (2011) 1.07
TRIM24 mediates ligand-dependent activation of androgen receptor and is repressed by a bromodomain-containing protein, BRD7, in prostate cancer cells. Biochim Biophys Acta (2009) 1.06
The rs10993994 risk allele for prostate cancer results in clinically relevant changes in microseminoprotein-beta expression in tissue and urine. PLoS One (2010) 1.01
FOXA1 promotes tumor progression in prostate cancer via the insulin-like growth factor binding protein 3 pathway. PLoS One (2012) 0.99
Opposite roles of FOXA1 and NKX2-1 in lung cancer progression. Genes Chromosomes Cancer (2012) 0.96
Forkhead-box A1 transcription factor is a novel adverse prognosis marker in human glioma. J Clin Neurosci (2013) 0.78